Roanoke man living with ALS is on a mission to help others
'I don't think you can ever be ready for a medical change that totally alters your trajectory in life,' said Mark Kary, who is living with ALS.
ALS is a neurotmesuclar disease where the brain stops communicating with the muscles. For some, a person might lose the ability to walk, talk, eat, breathe, and it can sometimes be fatal.
'If I want to go into my emails, I can scroll down with my nose,' shared Kary.
Mark Kary is 75 years old and is living with ALS. He said that right around the time of his retirement, he started to notice some weakness in his left arm.
'My brother, who was a doctor, found it, and that was about 12 years ago, which is a real anomaly time-wise. And I wasn't diagnosed until about five years ago,' said Kary.
Mark's version of ALS is extremely rare.
'Only affected thus far my arms, hands, and shoulders, which have atrophied or, as I like to say, my arms are for decoration only,' shared Kary.
Even with the diagnosis, the disease hasn't taken away his appetite for life.
Every day the sun comes up is a beautiful day. One of the things I say is, how I get things done is with the hands of others.'
Mark Kary
His arms, hands, and shoulders might not work as well as they used to, but that doesn't stop him; he said he just had to adapt.
'Think about personal hygiene, anything you can do with your hands. I can't do,' shared Kary. 'I can still brush my teeth with an electric toothbrush, but that does take, you know, a four-step process.'
I think you have to have a mission in life, no matter how brief.'
Mark Kary
'For most people who have ALS, they don't have the timeframe that I have been blessed with,' shared Kary.
And with the time Mark does have, he has created the ALS Red Ball Express. It's a visual and digital aid that you may have spotted on the back of cars.
'I want people to walk over and point their phone at it and get a connection to information,' said Kary.
Whether it's connecting people with information or raising funds for the ALS Association, Mark is on a mission to ensure there is a visual representation of ALS on the roads in Roanoke every day of the year.
Mark's story doesn't end, He's also been busy advocting for disabled people with adaptive access in Roanoke. A few years ago, he spoke with the City Manager, and helped put in place the Star City's first 'open access barrier-free parking' in downtown. Those are parking spaces specially set aside for disabled drivers, so they can park in timed spaces, for up to 10 hours.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
TransMedics Group, Inc. (TMDX): A Bull Case Theory
We came across a bullish thesis on TransMedics Group, Inc. on Global Equity Briefing's Substack by Ray Myers. In this article, we will summarize the bulls' thesis on TMDX. TransMedics Group, Inc.'s share was trading at $118.97 as of July 31st. TMDX's trailing and forward P/E were 59.75 and 62.11 respectively according to Yahoo Finance. A surgeon in a modern operating theatre performing a transplant surgery with medical technology. TransMedics is revolutionizing the organ transplant ecosystem through its Organ Care System, a technology designed to keep organs warm, oxygenated, and viable far longer than traditional cold storage. By tackling key bottlenecks—organ degradation, low utilization rates, and logistical constraints—Organ Care System significantly extends transplant windows and boosts usage rates. Clinical trial data highlights its transformative potential: expanded criteria lungs and hearts saw utilization jump to 87% and 81%, respectively, while DCD heart use rose from 0% to 89%. TMDX monetizes this impact through a razor-and-blade model—selling Organ Care System consoles and high-margin, single-use consumables—while providing end-to-end services through its National Organ Care System Program, a SaaS-like Organs as a Service platform. With 21 private jets, 17 procurement hubs, and trained staff, TMDX handles organ retrieval, transport, and maintenance, positioning itself as a logistics powerhouse in the transplant chain. The opportunity is vast: U.S. underutilization alone represents a $400M+ annual consumables revenue potential, and TMDX currently serves just 3% of the $39B global market expected by 2034. Future growth catalysts include a kidney Organ Care System by 2029, entry into international markets via a $200M facility in Italy, and scaling the National Organ Care System Program globally. Financially, the company achieved profitability in 2024, posting $441M in revenue and positive operating cash flow, though free cash flow remains negative due to capex-heavy expansion. Trading at a P/E of 91, investor returns hinge on continued execution, EU rollout, and successful kidney platform launch. If goals are met, the stock could double by 2030, but slower expansion or margin compression may limit upside. Previously, we covered a on TransMedics Group, Inc. by Oliver | MMMT Wealth in May 2025, which highlighted warm perfusion technology, strong execution, and real-time flight data as revenue indicators. The company's stock appreciated ~24% since Q1 outperformance played out. Ray Myers shares a similar view but emphasizes the SaaS-like NOP model and global expansion potential. TransMedics Group, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 23 hedge fund portfolios held TMDX at the end of the first quarter which was 29 in the previous quarter. While we acknowledge the potential of TMDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None.
Business Wire
a day ago
- Business Wire
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last patient, last visit in its ongoing Phase 2 clinical trial (NCT05561751) evaluating the safety and efficacy of GPC-100 (burixafor) in combination with propranolol and G-CSF in multiple myeloma patients undergoing autologous stem cell transplant (ASCT). Topline results from the study are expected in the fourth quarter of 2025. The randomized, open-label, multicenter study is designed to assess whether GPC-100, a small molecule CXCR4 antagonist, can improve CD34+ hematopoietic stem cell mobilization from the bone marrow into the peripheral blood, where they can be collected via leukapheresis for use in ASCT. In data presented at ASH 2024, GPC-100 appears to be well differentiated in terms of the speed with which it mobilizes stem cells compared to currently approved stem cell mobilization treatments. Dr. Muthalagu Ramanathan, Director of the Myeloma Program and Medical Co-Director of the Blood and Marrow Transplant and CAR-T Program at U Mass Memorial Health noted that 'traditionally, patients undergoing mobilization are required to come, as an outpatient, the night before their procedure to receive the mobilization injection — a process that adds logistical challenges. The study drug GPC100 needed to be administered just 45 minutes before stem cell collection and resulted in a successful mobilization, significantly improving the patient experience. This is a true blessing for our frail myeloma patients.' In addition to multiple myeloma and a planned Phase 1 study in acute myeloid leukemia (AML) patients, the company is also in discussions for potential collaborations that would utilize GPC-100's rapid and safe mobilization of stem cells in cell and gene therapy settings. About GPC-100 GPC-100 (burixafor) is a highly selective small molecule antagonist of CXCR4, a chemokine receptor that plays a central role in retaining hematopoietic stem cells in the bone marrow niche. By blocking CXCR4, GPC-100 may enhance the mobilization of these cells into the peripheral blood for collection and use in autologous stem cell transplant (ASCT) procedures. Originally developed by GPCR Therapeutics, Inc., GPC-100 became part of Exicure's pipeline following the company's acquisition in January 2025. In addition to multiple myeloma, GPC-100 is also being considered in acute myeloid leukemia (AML) and other diseases where improved stem cell mobilization could help enable more efficient and effective treatment approaches, such as sickle cell disease, rare diseases requiring autologous transplant, and cell and gene therapy settings. About Exicure Exicure, Inc. (Nasdaq: XCUR) is a clinical-stage biotechnology company developing therapies to address key challenges in hematologic diseases. The company's lead program, GPC-100, is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy. It is also being studied as a potential chemosensitizing agent in acute myeloid leukemia (AML). For more information, visit
Politico
a day ago
- Politico
Senate appropriators defend the NIH
WASHINGTON WATCH Senate appropriators came out hard in support of the National Institutes of Health on Thursday, giving the agency a $400 million funding boost for the 2026 fiscal year. How so: The Senate Appropriations Committee upped the agency's budget to $48.7 billion in the 2026 funding bill that cleared the panel with a 26-3 vote Thursday. If the bill becomes law, it would increase cancer research by $150 million; Alzheimer's research by $100 million and amyotrophic lateral sclerosis, or ALS, research by $25 million. The NIH's National Institute of Allergy and Infectious Diseases and the Office of Research on Women's Health would each get a $30 million boost. Research on maternal mortality, diabetes and rare diseases would also see an increase, among others. Why it matters: The funding boost is a rebuke from both Republicans and Democrats to the Trump administration's demand to decrease the NIH funding in the next fiscal year by as much as 40 percent, or $18 billion. Senate Appropriations Chair Susan Collins (R-Maine) said the legislation 'prioritizes funding to help make Americans healthier and supports life-saving medical research.' Sen. Patty Murray (D-Wash.), the top Democrat on the panel, said the budget increase was a message to 'the scientists wondering if there will even be an NIH by the end of this administration. This committee's resounding message is: 'Yes, Congress has your back.'' Murray urged scientists to continue their research in the U.S. despite the efforts of other countries to lure them away. The appropriators also adopted an amendment Thursday that would limit the Trump administration's control over NIH research funding. An amendment in the bill's manager's package limits the administration's plan to shift funding for most NIH grants from a multiyear schedule to an upfront single-year payment. The amendment states that no funds appropriated in the fiscal 2026 spending bill can be used to increase the proportion of grants fully funded in the first year of the award, compared with fiscal 2024. The NIH can only increase that proportion of forward-funded grants if the agency ensures it isn't cutting grants to do so. What's next: The bill is cleared for floor action. But congressional leaders haven't started bipartisan negotiations toward overall government funding totals, increasing the odds that lawmakers will again resort to a stopgap funding patch before the next fiscal year starts on Oct. 1. WELCOME TO FUTURE PULSE This is where we explore the ideas and innovators shaping health care. Peacock feathers have reflective structures that can amplify light into a laser beam, Science reports. Share any thoughts, news, tips and feedback with Carmen Paun at cpaun@ Ruth Reader at rreader@ or Erin Schumaker at eschumaker@ Want to share a tip securely? Message us on Signal: CarmenP.82, RuthReader.02 or ErinSchumaker.01. MORNING MONEY: CAPITAL RISK — POLITICO's flagship financial newsletter has a new Friday edition built for the economic era we're living in: one shaped by political volatility, disruption and a wave of policy decisions with sector-wide consequences. Each week, Morning Money: Capital Risk brings sharp reporting and analysis on how political risk is moving markets and how investors are adapting. Want to know how health care regulation, tariffs, or court rulings could ripple through the economy? Start here. WORLD VIEW A draft United Nations plan to make the world healthier no longer includes several targets cracking down on sugary drinks, trans fats and tobacco to prevent and control noncommunicable diseases globally. Struck down: A target of 80 percent of countries taxing sugary drinks at levels recommended by the World Health Organization by 2030, POLITICO's Rory O'Neill reports. That goal was a pillar of the initial draft, which will take the form of a nonbinding political declaration world leaders are expected to endorse at a Sept. 25 meeting in New York, on the margins of the U.N. General Assembly. The latest version has also dropped commitments to eliminate trans fats and aims instead to reduce them to the 'lowest level possible.' It also requires front-of-pack labels with nutritional information. A requirement for health warnings on tobacco packaging to be graphic and accompanied by elements that make it unattractive to consumers is also gone. The new draft has softer language on tobacco advertising, requiring countries to restrict it instead of eliminate it. 'Make no mistake, the Declaration in its current form is a backslide,' said Alison Cox, director of policy and advocacy at the NCD Alliance, in a statement. The alliance is a Switzerland-based civil society group working to promote chronic disease prevention. Why it matters: World leaders aim to reduce premature mortality from noncommunicable diseases such as heart disease, cancer and diabetes by 2030 through prevention and treatment and to improve mental health and well-being globally. Noncommunicable diseases killed 18 million people under age 70 in 2021, according to the WHO. Most deaths were in low- and middle-income countries. The aims align with the U.S. Health Secretary Robert F. Kennedy Jr.'s Make America Healthy Again agenda, but it's unclear how much the U.S. is involved in drafting the final text. HHS did not respond to a request for comment. What's next: Negotiators are meeting this week in New York to discuss the text.
